Literature DB >> 19486957

An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink.

W Katherine Yih1, James D Nordin, Martin Kulldorff, Edwin Lewis, Tracy A Lieu, Ping Shi, Eric S Weintraub.   

Abstract

Using a new sequential analytic method, the safety of tetanus-diphtheria-acellular pertussis (Tdap) vaccine was monitored weekly among subjects aged 10-64 years during 2005-2008. Encephalopathy-encephalitis-meningitis, paralytic syndromes, seizures, cranial nerve disorders, and Guillain-Barré syndrome were selected as outcomes based on previous reports and biologic plausibility. The risk following Tdap was not significantly higher than the risk after Td. Statistical power was sufficient to detect a relative risk of 4-5 for Guillain-Barré syndrome and 1.5-2 for the other outcomes. This study provides reassurance that Tdap is similar in safety to Td regarding the outcomes studied and supports the viability of sequential analysis for post-licensure vaccine safety monitoring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19486957     DOI: 10.1016/j.vaccine.2009.05.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Canada's eight-step vaccine safety program: Vaccine literacy.

Authors:  N Macdonald; L Pickering
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

Review 2.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

4.  Exact conditional maximized sequential probability ratio test adjusted for covariates.

Authors:  Ivair R Silva; Lingling Li; Martin Kulldorff
Journal:  Seq Anal       Date:  2019-05-13       Impact factor: 0.927

5.  Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.

Authors:  James G Donahue; Burney A Kieke; Edwin M Lewis; Eric S Weintraub; Kayla E Hanson; David L McClure; Elizabeth R Vickers; Julianne Gee; Matthew F Daley; Frank DeStefano; Rulin C Hechter; Lisa A Jackson; Nicola P Klein; Allison L Naleway; Jennifer C Nelson; Edward A Belongia
Journal:  Pediatrics       Date:  2019-11-18       Impact factor: 7.124

Review 6.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

7.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

8.  Alpha spending for historical versus surveillance Poisson data with CMaxSPRT.

Authors:  Ivair R Silva; Wilson M Lopes; Philipe Dias; W Katherine Yih
Journal:  Stat Med       Date:  2019-01-28       Impact factor: 2.373

9.  Composite sequential Monte Carlo test for post-market vaccine safety surveillance.

Authors:  Ivair R Silva
Journal:  Stat Med       Date:  2015-11-11       Impact factor: 2.373

10.  Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.

Authors:  Michael L Jackson; Onchee Yu; Jennifer C Nelson; James D Nordin; Sara Y Tartof; Nicola P Klein; James G Donahue; Stephanie A Irving; Jason M Glanz; Michael M McNeil; Lisa A Jackson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-06-03       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.